Alembic Pharmaceuticals Gains After U.S. FDA Issues Form 483 – Shares of the Vadodara-based drug maker rose as much as 4.2 percent, the most in over a month, to Rs 557.85 after the U.S. drug regulator issued Form 483 for its Panelav facility.
Read More :Alkem Labs Gains As U.S. FDA Conducts Audit At Daman Plant
The U.S. FDA inspection was conducted between March 12-20 and at the end of the inspection the regulator issued Form 483 with three observations. None of the observations are related to data integrity or repetitive in nature, Alembic Pharmaceuticals said in an exchange filing.
Meanwhile, the company is preparing the response to the observations, which will be submitted to the U.S. FDA shortly.
- Rupee Falls Below 90/USD: What This Big Slide Means for India Now
- Copper Prices Jump to Four-Month High as Supply Gets Tight — Prices Set for More Upside
- Wockhardt Share Jumps 19% on Heavy Buying — Why the Pharma Stock is Rising Today
- Spot Silver Above $56.10: Big Target $60–$62; MCX Silver Hits Fresh 52-Week High
- MCX Copper Price Forecast: Buy or Sell? Neal Bhai Explains the Next Big Move
Disclaimer
This article is intended for educational purposes only. The views and opinions expressed are those of individual analysts or brokerage firms and do not represent the views of GoldSilverReports.com. Investors are strongly advised to consult certified financial experts before making any investment or trading decisions.
| Follow us on |
| Telegram, Whatsapp , Facebook, Twitter, Instagram, YouTube, Google Business Profile and Truth Social. |
Comments are closed.